Brain Tumor Classification

Automated classification of brain tumors from MRI is a heavily published application of deep learning in medical imaging, with reported accuracies on public benchmarks routinely exceeding 98%. However, accuracy does not capture a critical dimension of benchmark quality: dataset integrity, defined as the independence of test from training data at the image, patient, and acquisition-source levels. We introduce a three-layer contamination framework comprising duplicate, patient, and source-label leakage to assess the public corpora on which this literature rests. We audit the three most widely used corpora against a chest-radiograph negative control and quantify each layer's effect on measured performance across nine architectures and three evaluation conditions. Contamination is severe at every layer: 28.8% of the dominant corpus's official test split has a near-twin in its own training split, a second corpus leaks 22.3% of its test images byte-identically, 95.5% of traceable test images share a patient with training, and file-header features containing no anatomy separate tumor from no-tumor at 0.959 balanced accuracy, at parity with fine-tuned ResNet backbones. The unexpected result is that removing every identified leaked test image leaves balanced accuracy essentially unchanged: stable performance after deduplication does not establish benchmark integrity. Our findings establish dataset integrity as a distinct, measurable axis of benchmark quality that a stable leaderboard cannot certify. For biomedical research, reported accuracy on these corpora alone does not establish that a model has learned to recognize tumors rather than exploit dataset-specific cues. We release the contaminated-file lists, recovered patient identifiers, and deduplicated splits.

Uncertainty Quantification (UQ) is a key requirement for trustworthy AI in high-stakes medical image analysis. In this work, we evaluate UQ in a multi-task Deep Learning framework for MRI-based glioma diagnosis that performs tumor segmentation and predicts IDH mutation status, 1p/19q co-deletion status, and tumor grade. Monte Carlo Dropout (MCD) is used for a detailed task-aware analysis of predictive, aleatoric, and epistemic uncertainty. We assess MC sample convergence, calibration, error detection, selective prediction, associations with segmentation performance, and the effect of voxel-wise uncertainty aggregation on case-level reliability. We also compare MCD with Deep Ensembles (DE) and Monte Carlo Deep Ensembles (MCDE), examine interactions between segmentation quality and classification, and evaluate a composite trust score integrating segmentation and classification uncertainty. Across tasks, uncertainty estimates supported meaningful error detection, while calibration depended on the dropout rate, with moderate rates yielding the most reliable probabilities. Uncertainty decomposition provided task-dependent interpretability but did not consistently improve error detection over predictive uncertainty alone. DE and MCDE showed comparable operational utility, with no method consistently dominating across tasks and metrics. The composite trust score did not consistently outperform classification uncertainty for selective prediction. Overall, our results provide a task-aware evaluation strategy and practical guidance for the development of trustworthy AI for glioma diagnosis.

We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted two proof-of-concept studies to validate its clinical utility in AI-clinician workflows: 1) a blinded multireader study where 12 neuroradiologists across varying experience levels interpreted 248 retrospective cases with or without AI assistance, and 2) a real-world prospective study in which 1,009 patients were independently and blindly assessed by BrainVLM and radiologists before surgery. Additionally, we demonstrated BrainVLM's utility in preoperative molecular subgroup prediction for adult-type diffuse gliomas, using a multi-center cohort of 632 patients. In primary evaluation, BrainVLM achieved an area under the curve (macro-AUC) of 0.85 (95% CI: 0.84-0.86), and an F1 score of 0.82 (95% CI: 0.81-0.83), surpassing neuroradiologists (F1 = 0.80 (95% CI: 0.79-0.81)). In external validation across 11 centers, BrainVLM achieved an AUC = 0.80 (95% CI: 0.79-0.82) and F1 = 0.75 (95% CI: 0.73-0.78), compared with F1 = 0.71 (95% CI: 0.69-0.73) for neuroradiologists. In prospective real-world evaluation, BrainVLM maintained performance comparable to neuroradiologists.

A capable brain-MRI report generator can still be, in effect, diagnostically silent. When a multi-chain chain-of-thought (CoT) reporter built on a medical Mistral-7B backbone is evaluated on held-out cohorts, it names most meningiomas and almost all metastases "glioma" (diagnosis recall 0.44/0.07). Yet the answer is not absent from the model: a supervised linear probe applied to its frozen segmentation features recovers the three tumour cohorts at 0.82 macro-F$_1$ (5-fold cross-validation; chance $\approx$0.33). We introduce NeuroFusion, an assistive reporter that surfaces this latent signal rather than overriding it: discriminative field-classifier heads over per-lesion features condition a fast, single-pass draft-then-review decoder on their committed outputs. Built on the identical Mistral backbone, this restores the diagnosis (meningioma 0.92, metastasis 0.75) and wins 8 of 9 prose-content comparisons across three held-out cohorts (RaTEScore, RadGraph-F$_1$, GREEN; Holm-corrected paired BCa), with no significant loss on the ninth, at 5-6x lower latency ($\approx$80 vs. 457 s/case). A controlled negative result sharpens the mechanism: a learned diagnosis pin that overrides the decoder instead of merely informing it collapses out-of-distribution metastasis recall to 0.03. Grammar-constrained decoding keeps 92.3% of records schema-valid, making every sentence entailment-checkable (7.5% contradicted vs. 36.8% for the direct baseline). In a blinded nine-case pilot, two board-certified neurologists independently rated NeuroFusion highest in every tumour type, the only system with zero critical errors, and gave it the top-rated sign-off in eight of nine cases (six outright, two ties).

Multimodal medical large language models remain structurally weak for neuro-oncology because volumetric evidence is compressed into generic visual tokens and diagnostic conclusions often lack an auditable link to MRI regions. We present NeuroMosaic, a 3D multimodal language model that converts multi-sequence brain MRI into anatomy-indexed regional tokens, aligns them with clinical narrative and molecular concepts, and generates evidence-linked outputs. The architecture combines a multi-resolution volumetric tokenizer, a neuroanatomical graph router, a molecular concept memory, and selective risk control. Across four glioma cohorts, NeuroMosaic achieved an internal subtype macro-F1 of 0.827 and external macro-F1 values of 0.784, 0.761, and 0.742. On UPenn-GBM, it improved over the strongest matched-input baseline by 3.6 percentage points (95% CI: 1.8 to 5.4, adjusted p = 0.0018), with IDH, 1p/19q, and MGMT AUROCs of 0.918, 0.861, and 0.781. Evidence pointing accuracy reached 0.703, and targeted evidence deletion reduced correct-answer probability by 0.187, compared with 0.046 for random deletion. These results establish anatomy-indexed routing as a measurable mechanism for accurate, grounded, and calibrated volumetric medical-language reasoning.

Brain tumor diagnosis is a time-sensitive process in which patients may wait weeks for a finalized pathology report. This problem motivates automated systems that classify tumor subtype from multimodal inputs. This paper details the DS@GT ARC team's work for ImageCLEFmed MEDIQA-CORE 2026 Task~1, Brain Tumor Subtype Classification. The task evaluates three glioma classification problems: Level-1 Molecular Type, LGG vs HGG, and WHO Grade. We combine pre-extracted MRI (NeuroVFM) and histopathology (Prov-GigaPath) embeddings with free-text radiology reports. Our team explored two trimodal fusion architectures, two report encoders (RadBERT and Llama-3.1-8B-Instruct), and a biologically motivated post-processing stage. We achieve a mean macro-F1 of 0.801 under the Fully Multimodal condition, exceeding the organizers' baseline of 0.796 and ranking second among the teams whose code passed verification. Additional evaluation across modality-dropping conditions shows that this advantage depends heavily on the availability of the histopathology modality, and that our system falls behind the baseline when modalities are missing. Our code is available on GitHub at https://github.com/dsgt-arc/imageclef-mediqacore-2026.

Glioma grading from tumor contours is often treated as a pixel problem even when the signal of interest is shape. We align closed contours with a functional shape-alignment framework, separate global deformation from residual Fourier shape, and organize these quantities as frequency-ordered tokens. In five-fold patient-disjoint cross-validation on BraTS~2020 tumor contours, with model selection performed using grouped inner validation, a compact multilayer perceptron (MLP) achieves the highest mean balanced accuracy at 71.5%, compared with 65.9% for ResNet-18 and 63.3% for ViT-Tiny. It also gives the highest mean low-grade glioma F1 at 54.9%. Its pooled out-of-fold balanced accuracy is 72.4% (patient-bootstrap 95% CI: 66.4--77.8%). The selected MLPs use 2.9k--117.3k parameters across folds, at least 46 times fewer than the pixel baselines. In a controlled noise-free simulation, shape-based models reach 56.3--71.5% balanced accuracy while the pixel models remain at 50.0--52.5%. This work demonstrates how incorporating a shape-based inductive bias at the representation level can improve interpretability and scalability while enabling substantial dimensionality reduction.

Self-supervised learning (SSL) has emerged as an effective paradigm for learning transferable representations from large-scale unlabeled whole slide images (WSIs). However, existing SSL methods primarily learn generic visual features and often fail to explicitly capture pathology-specific morphological patterns that are critical for disease characterization. To address this limitation, we propose Tiny Vision Transformer with Pathology-Aware Prototype Distillation (TVT-PAPD). This self-supervised pathology representation learning framework integrates a Tiny Vision Transformer (TVT) with a novel Pathology-Aware Prototype Distillation (PAPD) module. PAPD employs a learnable pathology prototype bank to discover and preserve representative tissue morphology patterns, encouraging semantically similar pathological regions to learn consistent and discriminative representations. The proposed framework enhances pathology-aware feature learning while maintaining computational efficiency with 90M parameters. Experiments on the Cancer Genome Atlas (TCGA) low-grade glioma (LGG)/glioblastoma (GBM) dataset and the Indian Pathology Brain (IPD-Brain) dataset demonstrate that TVT-PAPD achieves weighted F1-scores of 93.02% and 90.23%, respectively, for LGG-GBM classification, while exhibiting strong cross-cohort generalization across independent glioma datasets.

Access to sufficiently large biomedical datasets remains a major obstacle for machine learning in Raman spectroscopy-based diagnostics. In particular, for glioma analysis, datasets are typically small and heterogeneous, affected by acquisition-specific variability. This work investigates the utility of deep generative augmentation in such a small-cohort setting. We analyze glioma biopsy spectra acquired from 58 tumor samples and consider both binary IDH-status classification and 6-class methylation subtype classification problems. To address the limited size and imbalance of the dataset, we develop a conditional variational autoencoder ($β$-CVAE) capable of generating class-conditioned synthetic Raman spectra. The generated data are evaluated in Train-on-Synthetic, Test-on-Real (TS/TR) and Train-on-Synthetic+Real, Test-on-Real (TSR/TR) settings under a strict patient-isolated cross-validation protocol. Models trained exclusively on synthetic data underperform models trained on real spectra, indicating a substantial domain gap between synthetic and real distributions. However, augmenting the real training data with synthetic spectra consistently improves classification performance across multiple models. These findings indicate that, even with a limited number of independent patient samples, generative models can capture sufficient structure to provide useful regularization for downstream classifiers. We also investigate a reconstruction-based inference strategy, termed Classification by Reconstruction (CbR), in which class prediction is based on reconstruction error under different class conditions. Overall, the results support the use of deep generative augmentation as a practical strategy for improving machine learning robustness in Raman spectroscopy applications characterized by limited biomedical datasets.

NA methylation profiling has become a powerful approach for central nervous system (CNS) tumor classification, yet important challenges remain regarding cross-cohort transferability, methodological correctness, and robust multiclass evaluation. In this work, we propose a novel and methodologically rigorous machine-learning approach for methylation-based CNS tumor classification that combines Sparse Random Projection for dimensionality reduction with multinomial logistic regression for classification. We evaluate the proposed approach in the same general experimental setting established by a widely used reference classifier. On the 2,801-sample reference cohort, our method achieves a mean accuracy of 96% under stratified 3-fold cross-validation. On the independent 1,104-sample clinical evaluation cohort, it reaches 86% accuracy at the 91-class level and 93% when predictions are evaluated at the methylation class family level. These results improve upon the corresponding state-of-the-art reference figures of 82% class-level concordance and 88% family-level concordance, yielding absolute gains of approximately 4 and 5 percentage points, respectively. This improvement is clinically relevant: in a diagnostic setting, a 5-point increase in correct tumor classification can directly affect cancer subtype assignment and, in turn, influence treatment selection and downstream clinical decision-making. Our results show that the proposed model, grounded in stronger methodological practice in machine learning, consistently outperforms the previous state of the art across evaluation settings and can materially improve the reliability of CNS tumor classification.

Deep learning has shown significant potential in medical image analysis, particularly for disease detection using MRI scans. Accurate and early diagnosis of brain tumors remains challenging due to the complexity of brain structures and reliance on manual interpretation. This work presents an automated deep learning-based approach for brain tumor detection from MRI images using Convolutional Neural Networks and Residual Networks. Transfer learning is applied with two pretrained architectures, ResNet18 and ResNet50, to classify MRI scans into tumor and non-tumor categories. Experiments are conducted on a dataset of 3,929 brain MRI images, evaluating the impact of model depth and fine-tuning strategies. The results show that ResNet18 achieves a higher accuracy of 97% compared to 96% for ResNet50, demonstrating better generalization on limited medical data. The proposed framework enables fast, accurate, and cost-effective brain tumor detection, supporting early diagnosis and clinical decision-making.

This study introduces a computationally efficient convolutional neural network (CNN) architecture enhanced with transfer learning for multi-cancer detection using biomedical images. The proposed lightweight CNN model is designed to reduce computational complexity while maintaining high classification performance, making it suitable for deployment in resource-constrained environments. We evaluate this approach on three distinct tumor datasets comprising brain magnetic resonance imaging (MRI) and lung and kidney computed tomography (CT) scans. The model achieves test accuracy of 90.85 +- 2.22%, 98.64 +- 2.43% and 99.92 +- 0.08% for brain, lung, and kidney cancer classification, respectively, using 5-fold stratified cross-validation (CV). Transfer learning is employed by pretraining the model on one cancer type and fine-tuning it on the others, requiring only 20 additional epochs to achieve performance comparable to models trained from scratch. The fine-tuning process involves updating the classification part of the CNN and requires approximately 0.014 seconds per image per epoch using an NVIDIA GeForce GTX 960. Comparative evaluations show that the proposed model outperforms several state-of-the-art pretrained architectures, such as Xception, VGG16, VGG19, MobileNetV2 and DenseNet121. Overall, the model's effectiveness is evaluated across three types of cancer with distinct morphological characteristics, assessing its performance on both MRI and CT imaging modalities and demonstrating robust performance across diverse tasks and data types. These findings underscore the potential of streamlined deep learning (DL) frameworks in accelerating cancer diagnosis without sacrificing accuracy, especially in settings with limited computational resources.

Despite recent advancements in deep learning, accurately classifying brain tumors from MRI images continues to pose challenges. In this research, we present a comprehensive evaluation of five different convolutional neural networks (CNN) architectures, including a customized baseline model and four pre-trained models - for use in classifying multi-class brain tumors using a clinically-sourced dataset of approximately 10,000 MRI images. We have utilized five different architectures; VGG16, VGG19, DenseNet121, and EfficientNetB0, which were all tested and trained within an identical experimental framework. Performance was measured by both overall accuracy and tumor-wise recall as a means to measure the clinically-relevant performance of each architecture. We found that EfficientNetB0 had the best overall classification accuracy at 95%, when compared to the other architectures tested; specifically VGG16 (94.37%), VGG19 (92.29%), DenseNet121 (90.91%) and the customized CNN (78.00%). An especially important finding of our research was the considerable improvement in detecting meningiomas; specifically, while simple CNNs could detect meningiomas with a recall rate of approximately 20%, EfficientNetB0 was able to detect meningiomas with a recall rate of 89%. Meningiomas are often difficult to detect because they can appear very subtly on MRI images. Additionally, an interesting finding was that the deeper VGG19 performed worse than the shallower VGG16. This indicates that in many cases the architectural efficiency of a CNN model may be more important than its depth when working with medical images. Overall, EfficientNetB0 appears to provide the optimal trade-off between classification accuracy, number of parameters used in the model and clinically meaningful performance.

The noise of Magnetic Resonance Imaging MRI poses challenges for Deep Learning DL when tumor boundaries are obscured tumor location and appearance are complex Therefore we develop BrainFusionNet that combines Convolutional Neural Networks CNNs Vision Transformers ViT and Gated Recurrent Units GRUs to extract spatial contextual and sequential features from MRI images for improved brain tumor classification Furthermore explainable AI such as SHAP LIME and GradCAM are integrated to visualise and highlight image regions that contribute to BrainFusionNets decisionmaking process The proposed BrainFusionNet model is evaluated on two publicly available MRI datasets Kfold validation suggests 98 accuracy on both datasets The model was compared with the six stateoftheart SOTA CNNs and transfer learning Among the SOTA CNNs DenseNet121 and VGG16 achieved the highest accuracy of 96 The novelty of BrainFusionNet is that the hybrid model effectively extracts local and global features from MRI images even in smallscale tumor regions and small tumor sizes The model has a balanced sequential CNN architecture to capture lowlevel and deeperlayer features a customized ViT that captures local features stabilizes gradient flow and reduces the risk of vanishing gradients during MRI image training The CNN and ViT outputs are fed into a GRU for final classification Furthermore we analyze pixel intensities to determine whether MRI image quality affects image classification Our findings are very novel in image interpretation as we found that the distribution of pixel intensities in MRI images affects DL performance

Clinicians diagnose brain tumors by synthesizing patient symptoms, medical history, and quantitative imaging data from modalities such as MRI and CT scans into a unified clinical judgement. However, most deep learning models rely on MRI/CT images alone, failing to replicate the clinicians multimodal reasoning. We explore a two-branch multimodal network combining raw MRI scans with 91 extracted radiomic features (intensity, texture, shape, and boundary descriptors) to classify brain tumors into glioma, meningioma, pituitary, and no-tumor. A pre-trained CNN backbone encodes the image stream, whereas a dedicated MLP encodes the radiomic stream. Both streams are fused via concatenation, gated, or bidirectional cross-modal attention strategies. Across nine experimental runs on a balanced 7,200 image dataset, all multimodal configurations outperform unimodal baselines with gated fusion achieving the best accuracy of 96.13%.

Accurate brain tumor classification from magnetic resonance imaging (MRI) is a key requirement for early diagnosis and clinical decision-making. Vision Transformers (ViTs) have shown strong performance in medical image analysis by learning global contextual representations, but they often fail to capture intrinsic structural and topological patterns present in tumor regions. To address this limitation, we propose a fusion framework that combines Topological Data Analysis (TDA) features with pretrained Vision Transformer representations for four-class brain tumor classification. In the proposed method, TDA is used to extract complementary topological descriptors that capture geometric structure, connectivity, and shape information from MRI images. In parallel, a pretrained ViT model learns high-level semantic representations from the same images. These two feature spaces are then fused to form a unified and more discriminative representation for classification. The model is evaluated on the BRISC2025 dataset, which contains four brain tumor classes: glioma, meningioma, pituitary tumor, and non-tumor cases. Experimental results show that combining topological and transformer-based features significantly improves performance compared to using either approach alone. The proposed TDA-ViT fusion model achieves an accuracy of 99.10%, precision of 99.27%, recall of 99.15%, F1-score of 99.21%, and an AUC of 99.98%. It also outperforms several state-of-the-art models, including ResNet50, ResNet101, EfficientNetB2, and standalone Vision Transformers. These results demonstrate that topological features provide valuable complementary information that enhances deep representation learning, leading to a robust and highly accurate framework for automated brain tumor classification.

Healthcare models are transitioning from unimodal prediction toward multimodal reasoning over heterogeneous diagnostic inputs. In computational pathology, for complex tumor subtypes where morphology alone can be challenging to distinguish, pathology reports and molecular measurements may provide additional diagnostic evidence alongside whole-slide images, yet existing models often fail to clarify how diverse signals assemble into recognizable diagnostic concepts. We propose ConceptM$^3$oE (Concept Multimodal MoE), which embeds concept formation directly within interaction-aware mixture-of-experts (MoE) pathways. The architecture decomposes evidence into modality-specific, redundant, and synergistic experts, which are then projected into structured concept bottlenecks mapping latent features to a hierarchy of morphology and biomarker concepts. To prevent the information loss typical of interpretable bottlenecks, we utilize residual pathways within each expert to allow task-relevant signals to flow both through the concepts and directly to the final task prediction, so that high performance is maintained alongside interpretability. Across an institutional pediatric brain tumor cohort and a public glioma cohort, the framework delivers competitive performance to unconstrained models while producing reasoning traces validated by an independent neuropathologist. In data-limited regimes, ConceptM$^3$oE improves limited-data performance, increasing macro-F1 from 56.41% to 66.70% at small training sizes compared to non-concept-informed baselines, while also showing faster training convergence consistent with the regularizing effect of concept learning. This work offers a scalable path toward high-performance medical AI that is inherently verifiable and better aligned with the complex decision-making of clinical practice.

Generative augmentation is often proposed as a remedy for small medical-image datasets, but synthetic images are only useful when they improve downstream task performance. "Augmentation" here means synthetic supplementation: GAN-generated samples added to the real training pool, not geometric or photometric transforms of existing images. Twelve class-plane StyleGAN2-ADA generators were trained on constrained BRISC 2025 partitions to test whether their output, with or without InceptionV3 feature-space filtering, improves held-out tumour classification across three classifier families: a random forest (RF) on InceptionV3 features, a compact two-headed convolutional neural network (CNN), and MobileViTV2, a mobile hybrid convolutional-transformer. Each was evaluated at 1:1 and 1:2 real-to-synthetic ratios. An independent GPT-5.5 blind test placed gated real-versus-synthetic discrimination at 57.73% (95% CI: 54.48--60.92%) on the model-legible subset -- modestly above chance. The RF classifier did not benefit from the synthetic MRIs. The CNN showed consistent mean gains that did not survive Holm correction. MobileViTV2 showed the clearest benefit: filtered 1:1 augmentation improved tumour classification accuracy by 1.02% absolute (95% CI: 0.54--1.54%; Holm-corrected p = 0.0104). A secondary efficiency analysis found that every augmented CNN condition selected its checkpoint 42--64% earlier than baseline, while compute-matched MobileViTV2 runs reached selection after 50--67% fewer real-data epochs. Overall, augmentation utility was found to be architecture- and ratio-dependent, not guaranteed by visual fidelity alone.

Deep learning models have shown strong performance in medical image analysis, but deploying them in low-resource clinical environments remains difficult due to computational, memory, and power constraints. This paper presents a multi-strategy compression framework for brain tumor classification from MRI, encompassing quantization-aware training, knowledge distillation from a DenseNet-101 teacher to a compact DenseNet-32 student with low-bit post-training quantization, and Float16 post-training quantization on a lightweight MobileNetV2 backbone. Using a multi-class brain tumor MRI dataset containing glioma, meningioma, pituitary tumors, and healthy controls, we provide full experimental validation of the MobileNetV2-based pipeline, training the classifier through a three-stage transfer learning process and applying Float16 quantization via TensorFlow Lite. The DenseNet-based distillation and quantization-aware training strategies are described as complementary compression approaches within the framework, with their complete empirical evaluation reserved for future work. Experimental results on the MobileNetV2 pipeline show that the quantized model achieves 82.37 percent validation accuracy compared to the 82.20 percent full-precision baseline, reducing model size from 35.34 MB to 5.76 MB, a 6.14x compression ratio with no meaningful accuracy loss. Per-class evaluation confirms that quantization preserves diagnostic performance uniformly across all four tumor categories. These findings demonstrate that lightweight quantized models can deliver clinically viable brain tumor screening in resource-constrained healthcare settings.

Improving patient outcomes depends on the prompt and accurate diagnosis of brain tumors, but manual MRI scan analysis is still time-consuming and unreliable. Although deep learning has shown promise, many of the models that are now in use are computationally intensive and have difficulty handling the intrinsic complexity and variety of different types of brain tumors. In this work, we propose a lightweight yet high-performing Convolutional Neural Network (CNN) for multi-class brain tumor classification, employing MRI images to target gliomas, meningiomas, pituitary tumors, and healthy (no tumor) instances. The model was rigorously evaluated on two publicly accessible datasets from Figshare and Kaggle. Leveraging efficient feature extraction and optimized training strategies, our CNN achieved classification accuracies of 99.03% and 99.28%, along with ROC scores of 99.88% and 99.94% on Dataset 1 and Dataset 2, respectively-all while utilizing significantly fewer parameters than popular pre-trained architectures. In contrast to cutting-edge models like DenseNet201, MobileNetV2, VGG19, Xception, InceptionV3, and ResNet50, our approach consistently demonstrated superior performance with reduced computational overhead. These findings highlight the potential of the proposed model as a practical and reliable diagnostic aid in clinical environments.

The opaque nature of deep learning models remains a significant barrier to their clinical adoption in medical imaging. This paper presents a multimodal explainability framework that bridges the gap between convolutional neural network (CNN) predictions and clinically actionable insights for brain tumor classification, leveraging large language models (LLMs) to deliver human-interpretable diagnostic narratives. The proposed framework operates through three coupled stages. First, nine CNN architectures are extended with a dual-output hybrid formulation that simultaneously optimises a classification head and a segmentation head, enabling spatially richer feature learning. Second, visual saliency attribution methods, namely Grad-CAM, Grad-CAM++, and ScoreCAM, are applied to generate class-discriminative heatmaps, which are subsequently refined into binary tumor masks via an adaptive percentile thresholding pipeline. Third, the resulting masks are mapped onto the Harvard-Oxford cortical atlas to translate pixel-level evidence into named neuroanatomical structures, and the extracted findings are encoded into a structured JSON file that conditions three LLMs (Grok3, Mistral, and LLaMA) to generate coherent, radiological-style diagnostic reports. Evaluated on a dataset of 4,834 contrast-enhanced T1-weighted brain MRI images spanning three tumor classes, InceptionResNetV2 achieved the highest classification performance and Grad-CAM++ yielded the best segmentation overlap. Among the language models, Grok3 led in lexical diversity and coherence, while LLaMA achieved the highest readability score. By integrating visual, anatomical, and linguistic modalities into a unified pipeline, the framework produces explanations that are technically grounded and meaningfully interpretable, advancing the transparency and clinical accountability of artificial intelligence assisted brain tumor diagnosis.

The clinical integration of deep learning models for brain tumor diagnosis in neuro-oncology is severely constrained by limited expert-annotated MRI data and substantial inter-institutional domain shift arising from variations in scanners, imaging protocols, and contrast settings. These challenges significantly impair model generalization in real-world settings. To address this, we propose a novel orientation-aware unsupervised domain-adaptive framework for automated brain tumor classification using mixed 2D MRI slices. Initially, a CNN with large receptive field first categorizes input slices into axial, sagittal, and coronal views. For each orientation, a CNN architecture with ResNet50 backbone augmented with four fully connected layers is trained to extract discriminative features for tumor classification. To mitigate annotation scarcity and domain discrepancies, we introduce a slice-wise unsupervised domain adaptation strategy that transfers knowledge from the multi-modal such as T1, T2, and FLAIR source domain to the post-contrast T1 target domain. Feature-level alignment is enforced using maximum mean discrepancy loss, complemented by pseudo-label guided adaptation to preserve class discriminability. Extensive experiments demonstrate improved target-domain performance over prior approaches, highlighting the benefits of orientation-specific learning, multi-modal knowledge transfer, pseudo-label-guided adaptation, and unsupervised domain adaptation.

Classifying brain tumors using magnetic resonance imaging (MRI) is crucial for early diagnosis and treatment; however, tumor heterogeneity and a dearth of annotated datasets restrict the use of supervised deep learning approaches. In this work, we use self-supervised learning (SSL) to study multi-class brain tumor classification. Using a ResNet-50 backbone, we evaluate four SSL frameworks including SimCLR, BYOL, DINO, and Moco v3 on a publicly available dataset of 4,448 MRIs with 17 distinct tumor types. On the dataset, SimCLR achieved 99.64% accuracy, 99.64% precision, 99.64% recall, and 99.64% F1-score. The workflow includes preprocessing, fine-tuning, linear evaluation, and SSL pretraining with data augmentations. Results show that, when labels are limited, SSL-pretrained models outperform supervised baselines in terms of F1-score, recall, accuracy, and precision. Additionally, by providing visual insights into model decisions, Explainable AI techniques (Grad-CAM, Grad-CAM++, EigenCAM) enhance interpretability. These results demonstrate SSL's scalability and dependability in diagnosing brain tumors from unlabeled medical data.

Accurate intraoperative assessment of glioma infiltration is essential for maximizing tumor resection while preserving functional brain tissue. Fluorescence lifetime imaging (FLIm) offers real-time, label-free biochemical contrast, but its clinical utility is challenged by biological heterogeneity, class imbalance, and variability in histopathological labeling. We present a data-centric AI (DC-AI) framework that integrates confident learning (CL), class refinement, and targeted label evaluation to develop a robust multi-class FLIm classifier for glioblastoma (GBM) resection margins. FLIm data were collected from 192 tissue margins across 31 newly diagnosed IDH-wildtype GBM patients and initially labeled into seven tumor cellularity classes by an expert neuropathologist. CL was applied to quantify FLIm point-level confidence, identify label inconsistencies, and guide iterative class merging into a three-class scheme ("low", "moderate", "high"). The resulting high-fidelity dataset enabled training a model that achieved 96% accuracy in the three-class task. SHAP analysis revealed class-specific FLIm feature importance, highlighting distinct optical signatures across the infiltration spectrum. Targeted FLIm analysis further identified biological (e.g., gray matter composition) and acquisition-related (e.g., blood contamination) contributors to low-confidence predictions. Blinded re-evaluation of margins flagged by CL demonstrated intra-pathologist variability, underscoring the value of selective relabeling rather than exhaustive review. Together, these findings demonstrate that a DC-AI framework can systematically improve data reliability, enhance model robustness, and refine biological interpretation of FLIm signals, supporting the development of clinically actionable optical tools for real-time glioma margin assessment.

Early detection and classifying brain tumors using Magnetic Resonance Imaging (MRI) images is highly important but difficult to extract in medical images. Convolutional Neural Networks (CNNs) are good at capturing both local texture and spatial information whereas Vision Transformers (ViTs) are good at capturing long-range global dependencies. We propose a new hybrid architecture that combines a SqueezeNet-style CNN branch with a MobileViT-style global transformer branch, through an Adaptive Attention Gate mechanism, in this paper. The gate learns dynamically per-sample, per-feature weights to weight the contribution of each branch, allowing context-sensitive merging of local and global representations. The proposed model has a test accuracy of 97.60, a precision of 97.30, a recall of 97.50, an F1-score of 97.40, and a macro-average area under the curve (AUC) of 0.9946 with a trained and evaluated on the Brain Tumor MRI Dataset (Kaggle). These scores are higher than single CNN and ViT baselines, and current competitive fusion methods, showing that dynamic feature weighting is an effective way to classify medical images.

Brain tumors represent one of the most critical neurological conditions, where early and accurate diagnosis is directly correlated with patient survival rates. Manual interpretation of Magnetic Resonance Imaging (MRI) scans is time-intensive, subject to inter-observer variability, and demands significant specialist expertise. This paper proposes a deep learning framework for automated four-class brain tumor classification distinguishing glioma, meningioma, pituitary tumor, and healthy brain tissue from a dataset of 7,023 MRI scans. The proposed system employs a Vision Transformer (ViT-B/16) pretrained on ImageNet-21k as the backbone, augmented with a clinically motivated preprocessing and training pipeline. Contrast Limited Adaptive Histogram Equalization (CLAHE) is applied to enhance local contrast and accentuate tumor boundaries invisible to standard normalization. A two-stage fine-tuning strategy is adopted: the classification head is warmed up with the backbone frozen, followed by full fine-tuning with discriminative learning rates. MixUp and CutMix augmentation is applied per batch to improve generalization. Exponential Moving Average (EMA) of weights and Test-Time Augmentation (TTA) further stabilize and boost performance. Attention Rollout visualization provides clinically interpretable heatmaps of the brain regions driving each prediction. The proposed model achieves a test accuracy of 99.29%, macro F1-score of 99.25%, and perfect recall on both healthy and meningioma classes, outperforming all CNN-based baselines

Accurate diagnosis of pediatric brain tumors, starting with histopathology, presents unique challenges for deep learning, including severe data scarcity, class imbalance, and fine-grained morphologic overlap across diagnostically distinct subtypes. While pathology foundation models have advanced patch-level representation learning, their effective adaptation to weakly supervised pediatric brain tumor classification under limited data remains underexplored. In this work, we introduce an expert-guided contrastive fine-tuning framework for pediatric brain tumor diagnosis from whole-slide images (WSI). Our approach integrates contrastive learning into slide-level multiple instance learning (MIL) to explicitly regularize the geometry of slide-level representations during downstream fine-tuning. We propose both a general supervised contrastive setting and an expert-guided variant that incorporates clinically informed hard negatives targeting diagnostically confusable subtypes. Through comprehensive experiments on pediatric brain tumor WSI classification under realistic low-sample and class-imbalanced conditions, we demonstrate that contrastive fine-tuning yields measurable improvements in fine-grained diagnostic distinctions. Our experimental analyses reveal complementary strengths across different contrastive strategies, with expert-guided hard negatives promoting more compact intra-class representations and improved inter-class separation. This work highlights the importance of explicitly shaping slide-level representations for robust fine-grained classification in data-scarce pediatric pathology settings.

The scarcity of labeled clinical data in oncology makes Few-Shot Learning (FSL) a critical framework for Computer Aided Diagnostics, but we observed that standard Prototypical Networks often struggle with the "prototype instability" caused by morphological noise and high intra-class variance in brain tumor scans. Our work attempts to minimize this by integrating a non-linear Logistic Chaos Module into a fine-tuned ResNet-18 backbone creating the Chaos-Enhanced ProtoNet(CE-ProtoNet). Using the deterministic ergodicity of the logistic chaos map we inject controlled perturbations into support features during episodic training-essentially for "stress testing" the embedding space. This process makes the model to converge on noise-invariant representations without increasing computational overhead. Testing this on a 4-way 5-shot brain tumor classification task, we found that a 15% chaotic injection level worked efficiently to stabilize high-dimensional clusters and reduce class dispersion. Our method achieved a peak test accuracy of 84.52%, outperforming standard ProtoNet. Our results suggest the idea of using chaotic perturbation as an efficient, low-overhead regularization tool, for the data-scarce regimes.